List of Antibodies Companies in Norway - 5

Bionor Holding is a privately held biopharmaceutical company focused on advancing its proprietary therapeutic vaccines toward HIV cure.

Our innovative therapeutic approach targets upstream amplifiers of disease offering potential treatments across a diverse array of therapeutic indications. Calluna Pharma is a clinical stage biotech company driven by a commitment to improve patient outcomes in diseases where existing treatments are sub-optimal. We believe in the power of immunology to push boundaries, challenge the status quo, and develop therapies that will make a real difference for people living with serious diseases.

Curida is a Contract Development and Manufacturing Organization for Pharmaceuticals, based in Norway. We are building on more than 40 years of experience and offer premium quality manufacturing to international pharma companies. Curida has core competency on sterile and aseptic manufacturing of liquid pharmaceuticals. Our core technologies are blow-fill-seal (BFS) and nasal spray. We work with companies ranging from small biotech to Big Pharma. We have a lean and flexible organization that will, enabling a strong partnership with our customers.

Oncoinvent is a clinical stage company committed to developing new innovative radiopharmaceutical products for better treatment options for cancer patients. Radspherin®, the company’s lead product candidate is a novel alpha-emitting radioactive microsphere suspension designed for treatment of metastatic cancers in body cavities. Radspherin® has shown strong and consistent anticancer activity at essentially non-toxic doses in preclinical studies and is anticipated to potentially treat several forms of metastatic cancer. Situated in Oslo, Oncoinvent’s main offices include modern laboratory facilities suitable for cGMP and radiopharmaceutical manufacture for clinical trials and research. The development programs of the company include radiotherapeutic and radioimmunotherapeutic products with focus on alpha-emitting radionuclides for treatment of various solid cancers.

Thor Medical's primary market is to supply alpha emitters to suppliers and developers of innovative drugs targeting indications with high unmet medical needs, including any medical products and equipment. Going forward, the main business focus will be to refine the production technology, secure customer qualification and commitments, mature the manufacturing concept, and secure regulatory approvals and permits for industrialization.